VEGFA and retinopathy of prematurity: Recently, the application of anti-VEGF therapies, i.e., ranibizumab (Lucentis, Genentech) and bevacizumab (Avastin, Genentech), has played an important role in the treatment of neovascular eye diseases such as ROP, AMD, and central retinal vein occlusion [12].